Skip to main content
Shenzhen Bioeasy Biotechnology Co., Ltd. logo

Shenzhen Bioeasy Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 300942 ISIN · CNE100004C78 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 910 across all filing types
Latest filing 2025-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300942

About Shenzhen Bioeasy Biotechnology Co., Ltd.

https://www.bioeasy.com

Shenzhen Bioeasy Biotechnology Co., Ltd. specializes in the development, production, and marketing of rapid testing solutions for food safety, clinical diagnosis, and animal health. The company provides a comprehensive portfolio of diagnostic products, including rapid test strips, enzyme-linked immunosorbent assay (ELISA) kits, and automated detection instruments. Its core focus areas include the detection of antibiotic residues, mycotoxins, pesticides, and foodborne pathogens in dairy, meat, seafood, and grain products. In the clinical sector, Bioeasy offers point-of-care testing (POCT) solutions for infectious diseases and chronic conditions. The company emphasizes research and development to deliver high-sensitivity, user-friendly diagnostic tools that meet international quality standards. Its products are utilized by food producers, regulatory agencies, and healthcare providers to ensure safety and quality control across the global supply chain.

Recent filings

Filing Released Lang Actions
关于签订日常经营重大合同的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen EasyBio Technology Co., Ltd. regarding the signing of a significant daily operation contract with Chr. Hansen A/S. It details the contract terms, sales targets for 2025-2029, cooperation scope, and risk warnings. The document is relatively short (3200 characters) and focuses on the contract signing event rather than presenting financial statements or detailed financial performance data. It does not contain financial results, audit opinions, or management analysis. Therefore, it is not an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory certification or officer attestation. The document is a formal announcement of a material contract signing, which fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-04-25 Chinese
华兴会计师事务所(特殊普通合伙)关于营业收入扣除事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a specialized audit opinion on the deduction items from operating revenue for the fiscal year 2024 of Shenzhen Yirui Biotechnology Co., Ltd. It includes an auditor's report and a detailed table of revenue deductions. The document references an audit report and financial statements for the year ending December 31, 2024, but it is not the full annual report itself. Instead, it is a standalone audit-related report focusing on a specific aspect of the financials (revenue deductions) and includes the auditor's opinion on this matter. The document is 2475 characters long, which is relatively short and focused. It is not a general announcement or a certification letter but a specialized audit report. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2024
2025-04-24 Chinese
2024年度独立董事述职报告（熊莹)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2024" from Shenzhen Yirui Biotechnology Co., Ltd. It details the independent director's attendance at board and shareholder meetings, participation in committees, communication with internal audit, and other duties performed during the year 2024. It includes qualitative descriptions of the director's activities, compliance with laws and regulations, and oversight of company governance and financial reporting. The document is a narrative report on the independent director's duties and performance rather than a financial report, audit report, or announcement. It does not contain financial statements or earnings data, nor is it a regulatory filing or announcement of voting results. This type of document fits best under Board/Management Information (MANG), as it relates to management-level reporting on board activities and director responsibilities.
2025-04-24 Chinese
东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司2024年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2024年度持续督导跟踪报告" (2024 Annual Continuous Supervision Follow-up Report) issued by 东兴证券股份有限公司 regarding 深圳市易瑞生物技术股份有限公司. It contains detailed supervisory work overview, company performance analysis, fundraising project progress, share pledge information, management changes, regulatory measures, and other compliance-related content. The document is a comprehensive report on the sponsor's ongoing supervision and monitoring activities for the company during the year 2024. It is not a full annual report (10-K), nor an earnings release or audit report. It is a specialized regulatory/supervisory report related to the sponsor's duties and company compliance, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories and is a regulatory compliance document rather than a financial report or announcement.
2025-04-24 Chinese
东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司首次公开发行股票并上市之持续督导保荐总结报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导保荐总结报告书" which translates to a "Continuous Supervision Sponsorship Summary Report" related to the initial public offering (IPO) and listing of Shenzhen Yirui Biotechnology Co., Ltd. It is issued by Dongxing Securities as the sponsor institution. The content includes detailed descriptions of the sponsor's duties during the IPO and post-IPO continuous supervision period, including compliance with regulatory requirements, changes in project implementation, fundraising details, changes in sponsor representatives, company performance fluctuations, regulatory measures, and evaluations of cooperation with the issuer and other service institutions. The document contains substantive information about the ongoing supervision and sponsorship activities, fundraising, and company operations, but it is not a full annual or quarterly financial report, nor an earnings release or audit report. It is a detailed report summarizing the continuous supervision and sponsorship work related to the IPO and subsequent compliance. This type of document fits best under the category of "Regulatory Filings" (RNS) as it is a regulatory compliance and supervision summary report rather than a financial report or announcement of voting results, management changes, or capital updates. The document length (7121 characters) and detailed content confirm it is not a mere announcement or certification but a substantive regulatory filing report.
2025-04-24 Chinese
东兴证券股份有限公司关于深圳市易瑞生物技术股份有限公司开展外汇套期保值业务的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from Dongxing Securities Co., Ltd. regarding the foreign exchange hedging business of Shenzhen Yirui Biotechnology Co., Ltd. It includes descriptions of the hedging business, risk analysis, risk control measures, accounting policies, and the approval process by the board of directors, supervisory board, and the sponsor institution. The document is not a financial report, earnings release, or regulatory filing but rather a formal verification and opinion report related to a specific business activity (foreign exchange hedging). It does not fit into categories like Annual Report, Interim Report, or Capital Update. It is a standalone audit or verification type report related to internal controls and compliance, which aligns best with the Audit Report / Information (AR) category. The document length is under 5,000 characters but contains substantive content and detailed analysis, not just an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. Q1 2025
2025-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.